Application of compound in preparing medicine for treating acute pulmonary embolism

A technology for pulmonary embolism and a compound is applied in the application field of the compound in the preparation of a medicine for treating acute pulmonary embolism, and can solve problems such as reports on the effect of pulmonary embolism that have not yet been seen

Active Publication Date: 2019-02-01
PEKING UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far there is no report on the effect of prohematoxylin A and / or prohematoxylin B on pulmonary embolism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compound in preparing medicine for treating acute pulmonary embolism
  • Application of compound in preparing medicine for treating acute pulmonary embolism
  • Application of compound in preparing medicine for treating acute pulmonary embolism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Isolation and identification of prohematoxylin A

[0025] Hematoxylin dry heartwood (21kg), cut into small thin strips, reflux extraction with 8 times, 6 times, 6 times of 95% ethanol successively, 1 hour each time; the extract solution decompresses and recovers the solvent to obtain 95% ethanol extract. After evaporating the solvent until there is no alcohol smell, suspend in water, extract with petroleum ether, ethyl acetate, and n-butanol in sequence, and recover the solvents respectively to obtain 60 g of petroleum ether extract, 1400 g of ethyl acetate extract, and extract with n-butanol Material 360g.

[0026] Take 800g of ethyl acetate extract, and go through silica gel (100-200 mesh) column chromatography, chloroform-methanol=30:1, 20:1, 10:1, 5:1, 1:1 gradient elution, TLC comparison and combination A total of 14 fractions of Fr.A-Fr.N were obtained. Fraction Fr.E was subjected to silica gel (200-300 mesh) column chromatography, petroleum ether-et...

Embodiment 2

[0040] Example 2 Improvement effect of prohematoxylin A on lung index in rats with pulmonary infarction

[0041] 2.1 Test animals: SD rats, 8 weeks old, male, Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.

[0042] 2.2 Test drugs:

[0043] Protohematoxylin A (PTA) was dissolved in 0.5% CMCNa solution to prepare a 5 mg / mL drug solution.

[0044] 2.3 Grouping and handling of animals:

[0045] 40 SD rats, after one week of adaptive feeding, 8 in each group, were randomly divided into 5 groups: sham group (normal control group), model group (pulmonary infarction model group), PTA low-dose group (20mg / kg) , PTA high dose group (50mg / kg). The way of administration is intragastric administration.

[0046] Except for the normal control group, the animals in each group were subjected to the following operations:

[0047] One day before the operation and 40 minutes before the operation, the normal control group and the model group were given the same amount of nor...

Embodiment 3

[0059] Example 3 Effect of Protohematoxylin A on Respiratory Frequency of Rats with Pulmonary Infarction

[0060] 3.1 Test animals: SD rats, 8 weeks old, male, Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.

[0061] 3.2 Test drugs:

[0062] Protohematoxylin A (PTA) was dissolved in 0.5% CMCNa solution to prepare a 5 mg / mL drug solution.

[0063] 3.3 Grouping and handling of animals:

[0064] 40 SD rats, after one week of adaptive feeding, 8 in each group, were randomly divided into 5 groups: sham group (normal control group), model group (pulmonary infarction model group), PTA low-dose group (20mg / kg) , PTA high dose group (50mg / kg). The way of administration is intragastric administration.

[0065] Except for the normal control group, the animals in each group were subjected to the following operations:

[0066] One day before the operation and 40 minutes before the operation, the normal control group and the model group were given the same amount of no...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention finds application prospects of Protosappanin A and/or Protosappanin B in the preparation of a composition for preventing and/or treating acute pulmonary embolism. The present invention also provides application of the Protosappanin A and/or Protosappanin B in preparation of a medicament for preventing and/or treating acute and chronic complications caused by the acute pulmonary embolism.

Description

technical field [0001] The present invention relates to the application of prohematoxylin A and / or prohematoxylin B in the preparation of a composition for preventing and / or treating acute pulmonary embolism. Background technique [0002] Pulmonary embolism is a clinical and pathophysiological syndrome of acute pulmonary circulation disturbance caused by endogenous or exogenous emboli blocking the pulmonary artery and its branches. The main clinical and pathological features are pulmonary circulation and respiratory dysfunction. The disease has the characteristics of rapid onset, various clinical manifestations, easy misdiagnosis and missed diagnosis, and high mortality. At present, the treatment of acute pulmonary embolism mainly focuses on anticoagulation, thrombolysis, interventional and surgical treatment. Therefore, it is of great significance to develop new drugs for the treatment of acute pulmonary embolism, especially oral preparations. [0003] Protohematoxylin A ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61K31/335A61P11/00A61K31/352A61K31/616A61K31/37A61K31/4365A61K31/519A61P9/04A61P9/10A61P9/02A61P9/12A23L33/105A23L33/00
CPCA23L33/00A23L33/105A23V2002/00A61K31/335A61K31/352A61K31/365A61K31/37A61K31/4365A61K31/519A61K31/616A61P9/02A61P9/04A61P9/10A61P9/12A61P11/00A61K2300/00A23V2200/314A23V2200/30
Inventor 屠鹏飞曾克武赵明波姜勇
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap